Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03820817 · ClinicalTrials.gov registry record · Phase 1
Rifaximin in Patients With Monoclonal Gammopathy
A Phase 1 study of Waldenstrom Macroglobulinemia and Light Chain Deposition Disease, sponsored by Emory University.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03820817: Active Phase 1 study of Waldenstrom Macroglobulinemia and Light Chain Deposition Disease, sponsored by Emory University.
NCT03820817 is a Phase 1 study of Waldenstrom Macroglobulinemia and Light Chain Deposition Disease that is active but no longer recruiting, run by Emory University. The registered enrollment target is 50 participants, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03820817, a Phase 1 study of Waldenstrom Macroglobulinemia and Light Chain Deposition Disease, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.
Primary Outcome
Clinical response rate will be calculated as proportion (responders/total patients).
Conditions Studied
Interventions
- DRUG Rifaximin
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 1 |
What the registry record for NCT03820817 still lists
NCT03820817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (89% lower).
The record links to 9 conditions, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 1 intervention - of which Rifaximin is the first listed.
NCT03820817 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT03820817 about?
NCT03820817 is a clinical study titled "Rifaximin in Patients With Monoclonal Gammopathy". This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.
What is the current status of trial NCT03820817?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2019-05-15. Estimated completion is 2025-11-30.
What conditions does trial NCT03820817 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia, Light Chain Deposition Disease, Monoclonal Gammopathy, IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy.
What interventions are being tested in trial NCT03820817?
The interventions under investigation include: Rifaximin (DRUG).
Who is sponsoring clinical trial NCT03820817?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03820817 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03820817's enrollment target sits among peer trials
50 20th of 34 higher than 15 of 34 other Waldenstrom Macroglobulinemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Waldenstrom Macroglobulinemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
Study of SGR-1505 in Mature B-Cell Neoplasms
RECRUITING · Phase 1
-
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
RECRUITING · Phase 1
-
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI